Attendees Will Have Hands-on Opportunity to Experience Effectiveness
of Orbital Atherectomy at Treating Complex Calcium
ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--Nov. 6, 2012--
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), is offering 2012
VEITHsymposium™ attendees an opportunity to learn about the
effectiveness of orbital atherectomy in treating peripheral arterial
disease (PAD). Featuring live demos of the company’s revolutionary
Orbital Atherectomy System, a hands-on training lab and the chance to
engage with orbital atherectomy experts via CSIQ—the company’s official
medical education program—attendees can experience firsthand what it
takes to defeat complex arterial calcium.
Arterial calcification is a common, underdiagnosed condition with
complicating factors—including a higher frequency of dissections and
perforations—that pose a challenge for physicians treating PAD.
Calcified lesions are estimated to be present in approximately 65
percent of the people treated annually for PAD.
CSIQ Training Lab: Friday, Nov. 16
|
TIME:
|
|
|
3:30 – 6:30 p.m.
|
|
|
|
|
|
WHERE:
|
|
|
Hilton New York
|
|
|
|
|
1335 Avenue of the Americas
|
|
|
|
|
New York, NY
|
|
|
|
|
|
CSI Booth at VEITH: Nov. 14 – 16
Visit CSI at booth #1114/1116 9 a.m. – 5 p.m. Wednesday, Nov. 14,
through Friday, Nov. 16.
About Peripheral Arterial Disease
PAD is a life-threatening
condition where a fatty material called plaque builds up on the inside
walls of the blood vessels that carry blood from the heart to legs and
arms. The plaque buildup causes the arteries to harden and narrow
(atherosclerosis), reducing blood flow to the legs. The risk of PAD
increases if a person has one or several of the following: high blood
pressure, abnormal cholesterol levels, diabetes, or personal history of
heart disease, heart attack or stroke. PAD affects an estimated 8-12
million people in the United States. The disease prevalence increases
with age and 12-20 percent of Americans age 65 and older suffer from PAD
symptoms. As the U.S. population ages, the prevalence range could reach
16 million in those age 65 and older and 19 million overall by 2050.
About Cardiovascular Systems, Inc.
Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the
limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in
August 2007. To date, nearly 100,000 of CSI’s devices have been sold to
leading institutions across the United States. CSI has also commenced
its ORBIT II Investigational Device Exemption clinical trial to evaluate
the safety and effectiveness of its orbital technology in treating
coronary arteries. The coronary system is limited by federal law to
investigational use and is currently not commercially available in the
United States.
For more information, visit the company’s website at www.csi360.com.
Source: Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah
Wozniak, 651-259-1636
swozniak@csi360.com
or
Padilla
Speer Beardsley Inc.
Matt Sullivan, 612-455-1709
msullivan@padillaspeer.com
or
Dave
Folkens, 612-455-1741
dfolkens@padillaspeer.com